CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clin J Am Soc Nephrol 3: S3-S10, 2008
© 2008 American Society of Nephrology
doi: 10.2215/CJN.03250807
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bakris, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakris, G. L.

Article

Slowing Nephropathy Progression: Focus on Proteinuria Reduction

George L. Bakris

Hypertensive Diseases Unit, Section of Endocrinology, Diabetes and Metabolism, Pritzker School of Medicine, University of Chicago, Chicago, Illinois

Correspondence: Dr. George L. Bakris, University of Chicago, Pritzker School of Medicine, 5841 S. Maryland Avenue, MC 1027, Chicago, IL 60637. Phone: 773-702-7936; Fax: 773-834-0486; E-mail: gbakris{at}earthlink.net

Blood pressure control reduces decline of kidney function. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers offer renoprotection to a small extent beyond that attributable to blood pressure lowering. These agents also reduce proteinuria, a risk marker for renal disease progression. Accumulating evidence indicates that their antiproteinuric effect correlates with their additional renal benefits.




This article has been cited by other articles:


Home page
 NEJMHome page
J. R. Ingelfinger
Blood-Pressure Control and Delay in Progression of Kidney Disease in Children
N. Engl. J. Med., October 22, 2009; 361(17): 1701 - 1703.
[Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
L. F. Quintana, J. M. Campistol, M. P. Alcolea, E. Banon-Maneus, A. Sol-Gonzalez, and P. R. Cutillas
Application of Label-free Quantitative Peptidomics for the Identification of Urinary Biomarkers of Kidney Chronic Allograft Dysfunction
Mol. Cell. Proteomics, July 1, 2009; 8(7): 1658 - 1673.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
E. Ku, J. Park, J. Vidhun, and V. Campese
The Hazards of Dual Renin-Angiotensin Blockade in Chronic Kidney Disease
Arch Intern Med, June 8, 2009; 169(11): 1015 - 1018.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
A. M. O'Hare, J. S. Kaufman, K. E. Covinsky, C. S. Landefeld, L. V. McFarland, and E. B. Larson
Current Guidelines for Using Angiotensin-Converting Enzyme Inhibitors and Angiotensin II-Receptor Antagonists in Chronic Kidney Disease: Is the Evidence Base Relevant to Older Adults?
Ann Intern Med, May 19, 2009; 150(10): 717 - 724.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Society of Nephrology.